University of Windsor

Scholarship at UWindsor
Biological Sciences Publications

Department of Biological Sciences

1-10-2018

IL-10 correlates with the expression of carboxypeptidase B2 and
lymphovascular invasion in inflammatory breast cancer: The
potential role of tumor infiltrated macrophages
Hossam T. Mohamed
Noura El-Husseiny
Eslam A. El-Ghonaimy
Sherif A. Ibrahim
Zainab A. Bazzi

See next page for additional authors

Follow this and additional works at: https://scholar.uwindsor.ca/biologypub
Part of the Biology Commons

Recommended Citation
Mohamed, Hossam T.; El-Husseiny, Noura; El-Ghonaimy, Eslam A.; Ibrahim, Sherif A.; Bazzi, Zainab A.;
Cavallo-Medved, Dora; Boffa, Michael B.; El-Shinawi, Mohamed; and Mohamed, Mona M., "IL-10 correlates
with the expression of carboxypeptidase B2 and lymphovascular invasion in inflammatory breast cancer:
The potential role of tumor infiltrated macrophages" (2018). Current Problems in Cancer.
https://scholar.uwindsor.ca/biologypub/1183

This Article is brought to you for free and open access by the Department of Biological Sciences at Scholarship at
UWindsor. It has been accepted for inclusion in Biological Sciences Publications by an authorized administrator of
Scholarship at UWindsor. For more information, please contact scholarship@uwindsor.ca.

Authors
Hossam T. Mohamed, Noura El-Husseiny, Eslam A. El-Ghonaimy, Sherif A. Ibrahim, Zainab A. Bazzi, Dora
Cavallo-Medved, Michael B. Boffa, Mohamed El-Shinawi, and Mona M. Mohamed

This article is available at Scholarship at UWindsor: https://scholar.uwindsor.ca/biologypub/1183

Author’s Accepted Manuscript

image

IL-10 correlates with the expression of
carboxypeptidase B2 and lymphovascular invasion in
inflammatory breast cancer: The potential role of tumor
infiltrated macrophages
Hossam Taha Mohamed, Noura El-Husseiny, Eslam A.
El-Ghonaimy, Sherif Abdelaziz Ibrahim, Zainab A.
Bazzi, Dora Cavallo-Medved, Michael B. Boffa,
Mohamed El-Shinawi, Mona Mostafa Mohamed

PII:
DOI:
Reference:

www.elsevier.com/locate/bios

S0147-0272(17)30120-4
https://doi.org/10.1016/j.currproblcancer.2018.01.009
YMCN375

To appear in: Current Problems in Cancer
Cite this article as: Hossam Taha Mohamed, Noura El-Husseiny, Eslam A. ElGhonaimy, Sherif Abdelaziz Ibrahim, Zainab A. Bazzi, Dora Cavallo-Medved,
Michael B. Boffa, Mohamed El-Shinawi and Mona Mostafa Mohamed, IL-10
correlates with the expression of carboxypeptidase B2 and lymphovascular
invasion in inflammatory breast cancer: The potential role of tumor infiltrated
m a c r o p h a g e s , Current
Problems
in
Cancer,doi:10.1016/j.currproblcancer.2018.01.009
This is a PDF file of an unedited manuscript that has been accepted for
publication. As a service to our customers we are providing this early version
of the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting galley proof before it is published in its final citable
form. Please note that during the production process errors may be discovered
which could affect the content, and all legal disclaimers that apply to the
journal pertain.

IL-10 correlates with the expression of carboxypeptidase B2 and lymphovascular
invasion in inflammatory breast cancer: the potential role of tumor infiltrated
macrophages
1

Hossam Taha Mohamed , Noura El-Husseiny1, Eslam A. El-Ghonaimy 1, Sherif Abdelaziz
Ibrahim1, Zainab A. Bazzi2, Dora Cavallo-Medved3, Michael B. Boffa2, Mohamed ElShinawi4,5 and Mona Mostafa Mohamed1,5*

1

Department of Zoology, Faculty of Science, Cairo University, Giza, 12613, Egypt.

2

Department of Biochemistry, University of Western Ontario, London, Ontario, N6A 3K7,

Canada.
3

Department of Biological Sciences, University of Windsor, Ontario, N9B3P4, Canada.

4

Department of General Surgery, Faculty of Medicine, Ain Shams University, Cairo, 11566,

Egypt.
5

Breast-Gynecological International Cancer Society, Cairo, Egypt.

*Corresponding author:
Mona Mostafa Mohamed, Ph.D.
Department of Zoology, Faculty of Science, Cairo University, 12613, Giza, Egypt.
Email: mmostafa@sci.cu.edu.eg
Tel. +2-02-35676720
Fax. +2-02-35727556
Abstract
Background:
Pro-carboxypeptidase B2 (pro-CPB2) or thrombin-activatable ﬁbrinolysis inhibitor (TAFI) is
a glycoprotein encoded by the CPB2 gene and deregulated in several cancer types, including
breast cancer. Thrombin binding to thrombomodulin (TM), encoded by THBD, is important
for TAFI activation. CPB2 gene expression is influenced by genetic polymorphism and
cytokines such as interleukin 10 (IL-10). Our previous results showed that tumor infiltrating
monocytes/macrophages (CD14+/CD16+) isolated from inflammatory breast cancer (IBC)
patients’ secrete high levels of IL-10. The aim of the present study is to test genetic
polymorphism and expression of CPB2 in healthy breast tissues and carcinoma tissues of
1

non-IBC and IBC patients. Furthermore, to investigate whether IL-10 modulates the
expression of CPB2 and THBD in vivo and in-vitro.
Materials and methods
We tested CPB2 Thr325Ile polymorphism using restriction fragment length polymorphism,
(RFLP) technique in healthy and carcinoma breast tissues. The mRNA expression of CPB2,
THBD and IL10 were assessed by RT-qPCR. Infiltration of CD14+ cells was assessed by
immunohistochemistry. We investigated the correlation between infiltration of CD14+ cells
and expression of IL10 and CPB2. Furthermore, we correlated IL10 expression with the
expression of both CPB2 and THBD in breast carcinoma tissues. Finally, we validated the
role of recombinant IL-10 in regulating the expression of CPB2 and THBD using different
breast cancer cell lines.
Results:
Our data showed that CPB2 genotypes carrying the high-risk allele [Thr/Ile (CT) and Ile/Ile
(TT)] were more frequent in both IBC and non-IBC patients compared to control group.
CPB2 genotypes did not show any statistical correlation with CPB2 mRNA expression levels
or patients’ clinical pathological properties. Interestingly, CPB2 and IL10 expression were
significantly higher and positively correlated with the incidence of CD14+ cells in carcinoma
tissues of IBC as compared to non-IBC. On the other hand, THBD expression was
significantly lower in IBC carcinoma versus non-IBC tissues. Based on molecular subtypes,
CPB2 and IL10 expression were significantly higher in triple negative (TN) as compared to
hormonal positive (HP) carcinoma tissues of IBC. Moreover, CPB2 expression was
positively correlated with presence of lymphovascular invasion and the expression of IL10 in
carcinoma tissues of IBC patients. Furthermore, recombinant human IL-10 stimulated CPB2
expression in SUM-149 (IBC cell line) but not in MDA-MB-231 (non-IBC cell line), while
there was no significant effect THBD expression.
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Conclusion:
Carcinoma tissues of IBC patients are characterized by higher expression of CPB2 and lower
expression of THBD. Moreover, CPB2 positively correlates with IL10 mRNA expression,
incidence of CD14+ cells and lymphovascular invasion in IBC patients. IL-10 stimulated
CPB2 expression in TN-IBC cell line suggests a relevant role of CPB2 in the aggressive
phenotype of IBC.
Keywords:
Inflammatory breast cancer, carboxypeptidase B2, thrombin-activatable ﬁbrinolysis inhibitor,
interleukin-10, thrombomodulin, macrophages, lymphovascular invasion.

Introduction:
Inflammatory breast cancer (IBC) is a particularly aggressive and highly metastatic form of
breast cancer. The progression of IBC is associated with (lymph) angiogenesis, and a
pronounced ability for lymphovascular invasion and formation of lymphatic tumor emboli
that promote metastasis and dissemination to different organs [1-3]. In addition, the overall
survival (OS) and breast cancer-specific mortality (BCSM) of IBC are higher among patients
with a triple negative (TN) molecular subtype as compared to others [4]. In this regard, novel
therapeutic options that target TN-IBC molecular subtype should be considered [5].
Case report studies from different countries showed that IBC may be associated with
thrombosis. For instance, a 54-year-old woman initially diagnosed with spontaneous brachial,
axillary, and subclavian venous thrombosis was also found to have late stage IBC [6].
Another study showed that an IBC patient presented early with arm lymphoedema and
venous thromboembolism (VTE) [7]. Serra and colleagues reported that axillary vein
thrombosis may be considered as the first clinical manifestation of IBC [8]. Indeed, VTE
increases the rate of morbidity and mortality among cancer patients. The incidence of VTE
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has increased in the past 2 decades [9], and 20% to 30% of VTE cases were found to be
associated with the development of cancer [10]. Studying the relationship between
thromboembolism and cancer may provide novel insights for early diagnosis of the disease
[7].
One of the proteins associated with the formation of VTE is pro-carboxypeptidase B2 (proCPB2), also known as thrombin activatable fibrinolysis inhibitor (TAFI) [11]. pro-CPB2 is a
glycoprotein, encoded by CPB2, synthesized mainly in the liver as a 60-kDa zymogen, and
proteolytically activated by plasmin, thrombin or the thrombin-thrombomodulin complex
[12]. The active form pro-CPB2, known as CPB2 or TAFIa, is a 35-kDa basic
carboxypeptidase [13]. CPB2 inhibits lysis of the fibrin clot by removing C-terminal lysine
residues from partially-degraded fibrin, attenuating plasminogen activation and ultimately
fibrinolysis [14].
Previous studies showed that pro-CPB2 protein might be associated with poor prognosis of
cancer. For instance, pro-CPB2 is highly secreted from lung carcinoma cells and plays a
crucial role in the pathogenesis of thrombotic disorders in lung cancer patients [15]. Another
study reported high pro-CPB2 levels in the advanced colorectal cancer patients as compared
to those showing localization of cancer cells in the colon [16]. Serum pro-CPB2 levels are
significantly higher in breast cancer patients as compared to healthy control. High levels of
pro-CPB2 may be associated with thrombotic disorders in breast cancer patients [17]. A
Chinese study suggested that CPB2 Thr325Ile polymorphism might be considered a risk
factor for development of breast cancer in Chinese Han populations [18]. A pilot study
assessing pro-CPB2 level in plasma of Egyptian breast cancer patients showed an increase in
pro-CPB2 plasma level that is correlated with advanced stages, poor prognosis and high risk
of disease recurrence. Furthermore, CPB2 Thr325Ile polymorphism was associated with the
development of breast cancer in Egyptian population [19].
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The anticoagulant/antifibrinolytic factor thrombomodulin (TM) encoded by THBD gene is a
type 1 transmembrane glycoprotein [20, 21] that has the ability to regulate inflammation and
tumor promotion [22-25]. THBD expression in carcinoma tissues is associated with less
advanced stage and a better prognosis in several cancers [26-28]. Thrombin binding to TM is
important for the physiological activation of pro-CPB2 to CPB2 and has been shown to be
responsible for the anti-metastatic effects of TM [29]. Furthermore, CPB2 has been shown to
inhibit cell invasion and motility of breast carcinoma cells [30].
Interleukin 10 (IL-10) is “double-edged sword” cytokine as it displays both pro and antitumor activities [31]. It is suggested that IL-10 is expressed at a higher level by metastatic
cancer cells to down regulate the inflammatory response of cell-mediated immunity [32]. IL10 levels in serum of breast cancer patients were associated with disease initiation and
progression [33]. A recent study reported higher expression level of IL-10 in the examined
breast cancer tissue, and increased IL-10 expression associated with poor prognosis [34].
Indeed, the tumor microenvironment of IBC patients is characterized by the activation of
different signaling pathways such as NF-B, COX-2, and JAK/STAT, which induce the
expression and secretion of various pro- and anti-inflammatory cytokines [35, 36]. Our
previous studies showed that IL-10 is over expressed by tumor-associated macrophages
isolated from IBC patients [35, 36]. Recently we found that the expression of IL10 in IBC
carcinoma tissues correlate with GCC haplotypes (-1082A/G, -819T/C, and -592A/C) in the
gene promoter region [37].
Many studies have shown a differential role for cytokines including IL-10 in regulating the
expression of CPB2 in different cell lines. For example, the treatment of human
hepatocellular carcinoma cell line, HepG2, with TNFα or IL-6 in combination with IL-1β, or
bacterial lipopolysaccharide (LPS) for 24-48 h decreases expression of pro-CPB2 protein by
two-fold. Additionally, IL-10 increases the expression of CPB2 mRNA in HepG2 cell line
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[38]. In the present study, we examined the mRNA expression level of CPB2, THBD and
IL10 in non-IBC and IBC carcinoma tissues, and whether the CPB2 Thr325Ile polymorphism
affects expression of CPB2. Furthermore, we investigated the effects of IL-10 on the
expression of CPB2 and THBD in vivo and in-vitro.

Materials and Methods:
Patients and Samples
For patient enrolment we obtained an institutional Review Board (IRB) approval from the
ethics committee of Faculty of Medicine, Ain Shams University, Egypt. Patients were
diagnosed with non-IBC or IBC by clinical ultrasound examination, mammography and trucut biopsy [36, 39]. A total of 135 breast cancer patients (91 non-IBC and 44 IBC) and 50
healthy volunteers were enrolled in the present study. Carcinoma tissues were obtained
during modified radical mastectomy (MRM). Normal breast tissues were obtained from
healthy volunteers undergoing mammoplasty. All enrolled healthy volunteers and breast
cancer patients signed informed consent that agrees with publication of anonymous data.
Quantitative real-time Polymerase chain reaction (RT-qPCR)
Total RNA was extracted from 30 mg of fresh breast tissues (normal and carcinoma) and
breast cancer cell lines MDA-MB-231 and SUM-149 using GeneJETTM RNA Purification Kit
(Thermo scientific, ON, Canada). RNA concentration was measured using Infinite®200 PRO
NanoQuant (Tecan, Männedorf, Zürich, Switzerland) and 1 µg was reversed transcribed into
complementary DNA using RevertAid First Strand cDNA Synthesis Kit (Thermo scientific,
ON, Canada). Quantitative PCR was performed as described before [40, 41] via using
StepOnePlus 96 well device (Applied Biosystems, San Francisco, CA, USA) and in a 25 μl
total volume of 12.5 μl SYBR green master mix (Applied Biosystems, Darmstadt,
Hesse, Germany), 0.5 μl of each CPB2 upstream 5′-GCTGCCGGAGCGTTACAT-3′ and
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CPB2

downstream

5′-CATTCCTAATGACATGCCAAGCT-3′,

THBD

upstream

5′-

CCCTGAACAAGAAT TGGAAGCT -3′ and THBD downstream 5′- GGAGCCTAGGATT
CTGCATTTCTA-3′, and IL10 upstream 5′- GCCACCCTGATGTCTCAGTT -3′ and IL10
downstream 5′- GTGGAGCAGGTGAAGAATGC -3′ primers (10 pmol/μl), 2.5 μl of cDNA
and 8 μl of RNase free water. Reaction thermal profile started with initial denaturation at
95C for 10 min, then followed by 40 cycle of 94C for 15 sec and 60C for 1 min.
Ampliﬁcation speciﬁcity was veriﬁed using melting curve analysis and 2% agarose gel
electrophoresis of the PCR products. Data were analyzed using the 2-∆∆Ct method after
normalization to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Qiagen, Valencia,
CA, USA) (10 pmol\μl).
Restriction Fragment Length Polymorphism (RFLP)-PCR assay for CPB2 (Thr325Ile)
polymorphism
DNA was extracted from breast tissues by using GeneJETTM Genomic DNA purification Kit
(Thermo scientific, ON, Canada). The RFLP-PCR assay was carried out in a 25 μl total
volume using 1μl of each designed CPB2 upstream 5′-TTCAAAGCTGCACATTAACTG-3′
and CPB2 downstream 5′-CTTTAGTAGCTCAAA GTTCTC-3′ primers (10 pmol/μl), 3 μl of
DNA extract (250 ng DNA), 12.5 μl of EmeraldAmp® MAX PCR green master mix and
7.5 μl of free RNase water. The PCR thermal profile started with an initial denaturation at 94
ºC for 5 min, followed by 35 cycles at 94 ºC for 45 sec, 54 ºC for 1 min, and 72 ºC for 45 sec,
followed by terminal extension at 72 ºC for 10 min. The PCR product has an expected size of
200 bp. Following PCR, the PCR product was digested by SpeI restriction enzyme (10U)
(Takara, Dalian, China) for 2 h at 37 ºC and subject to agarose gel electrophoresis. The digest
PCR products migrated bands were visualized on 2% agarose gels by using iBox Scientia 615
Imaging System (UVP Upland, CA, USA). Samples with CC genotype showed digestion
with SpeI was represented by a band at 100 bp. Samples with TT genotype did not show
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digestion with SpeI was represented by a band at 200 bp. Samples with both genotypes CT
bands at 100 bp and 200 bp were detected as described before [42]. Twenty percent of
samples were re-genotyped in separate runs to exclude the possibility of false genotyping.
Immunohistochemistry
Immunohistochemical (IHC) staining was performed on 4 μm thick paraffin embedded tissue
sections as we described before [43] using antibodies against CD14 (1:50) (Chemicon,
Temecula, CA, USA) and CD68 (1:50) (DakoCytomation, Glostrup, Denmark). Staining was
achieved by adding 100 µl of DAB+ chromogen diluted 1:50 in substrate buffer [EnVision+
Dual Link System-HRP (DAB+)] for 10 min. Finally, tissue specimens were rinsed three
times in phosphate buffer saline (PBS), the nuclei were counterstained with hematoxylin and
mounted using Permount® for microscopic examination. The stained area fractions were
calculated using image J software (National Institutes of Health, Bethesda, MD, USA).
Sodium dodecyl sulfate polyacrylamide gel electrophoresis and immunoblotting
Protein content of fresh breast carcinoma tissues lysates was assessed by Bradford assay [44].
Equal concentration of tissue protein lysates (30 μg/well) were subjected to 10% SDS-PAGE,
followed by transfer to Polyvinylidene fluoride (PVDF) membrane (Millipore, Darmstadt,
Germany). The membranes were blocked for 1 h with 5% non-fat dry milk in TBS-0.5%
Tween 20, followed by incubation overnight at 4 oC with anti-IL-10 (R&D systems, MN,
USA) (1:100) then washed and incubated for 1 h with 1:10000 diluted peroxidase-labeled
goat anti-rabbit secondary antibody. After washing, the bands were visualized by using Pierce
ECL immuno-blotting substrate (Thermo Fisher Scientific, Rockford, IL, USA). Signals
representing protein bands were captured with the iBox Scientia 615 Imaging System (UVP
Upland, CA, USA). Visualized protein bands were analyzed by ImageJ (National Institutes of
Health, USA.) software and quantified relativity to β-tubulin as loading control [44].
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Effect of recombinant human IL-10 on the expression of CPB2 by breast cancer cell
lines
We studied the effect of recombinant human IL-10 on MDA-MB-231 (non-IBC) and
SUM149 (IBC) cell lines (gift from Dr. Bonnie Sloane, Department of Pharmacology, Wayne
State University, Detroit, MI, USA). Cell lines were cultured as previously described [36,
45]. MDA-MB-231 and SUM-149 cells were seeded at the density of (3.5 × 105/well) in six
well plate and incubated at 37°C and 5% CO2 for 24 h in appropriate complete media, Ham’s
F.12 containing 5% FBS and DMEM containing 10% FBS for SUM149 and MDA-MB-231,
respectively [45, 46]. Cultured media were removed and cells incubated in serum free media
conditioned with recombinant IL-10 (R&D systems, Minneapolis, Minnesota, USA) at
concentrations of 100, 200 and 400 ng/ml for 24 h [36]. Then cells were washed twice with
cold PBS and total RNA extracted.
Statistical Analysis
Data were expressed as mean ± standard deviation (SD). Statistical difference between
groups was assessed by Student’s t-test and Chi square test. P values ˂ 0.05 were considered
to be statistically signiﬁcant. To determine the association between CPB2 Thr325Ile
polymorphism and the development of breast cancer we used Hardy-Weinberg equilibrium to
compare the genotype frequencies in cancer patients and the healthy control group. Logistic
regression was used to calculate the odds ratios (OR) and 95% confidence interval (CI) to
estimate the relative association between breast cancer development and a particular allele
and genotype using SNPstat software [47, 48]. Correlation was assessed by Pearson’s
correlation coefficient using SPSS 22.0 software.
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Results:
Clinical and pathological characterization of breast cancer patients
Clinical and pathological characterization of non-IBC and IBC patients was described in
Table 1. Statistical analysis showed that IBC patients were characterized with significantly
larger tumor size (p = 0.003) in comparison with non-IBC patients. Moreover, the status of
lymph node metastasis and lymphovascular invasion in IBC patients was significantly higher
(p = 0.002 and 0.001, respectively) than non-IBC patients.
Incidence of CPB2 genotypes carrying the high-risk allele [Thr/Ile (CT) and Ile/Ile (TT)]
was higher in breast cancer patients compared to healthy volunteers
The genotypes and alleles distributions for the CPB2 Thr325Ile polymorphism are presented
in Table 2. The genotype distribution of both studied groups’ ﬁts the Hardy–Weinberg
equilibrium (p > 0.05). The incidence of CPB2 genotypes carrying the high-risk allele
[Thr/Ile (CT) and Ile/Ile (TT)] was signiﬁcantly higher (p = 0.003) in breast cancer patients in
comparison with healthy volunteers (OR: 0.32; [95% CI: 0.16-0.64]; P = 0.001). We did not
detect a statistically signiﬁcant difference in the incidence of CPB2 genotypes carrying the
high-risk allele [Thr/Ile (CT) and Ile/Ile (TT)] between non-IBC and IBC patients. CPB2
mRNA expression level did not show a statistical correlation with the incidence of CPB2
genotypes carrying the high-risk allele [Thr/Ile (CT) and Ile/Ile (TT)] in each of healthy
volunteers and breast cancer patients or even among patient non-IBC and IBC subgroups
(Supplementary Table 1). In addition, there was no association between the incidence of
CPB2 genotypes carrying the high-risk allele [Thr/Ile (CT) and Ile/Ile (TT)] and patients’
clinical pathological properties including tumor grade, tumor size, lymphovascular invasion,
lymph node status, expression of ER, PR and Her-2 in each of non-IBC and IBC patient
groups (Supplementary Tables 2 & 3).
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CPB2 mRNA expression level is higher in triple negative (TN) breast carcinoma tissues
of non-IBC and IBC patients in comparison to hormonal positive (HP), and positively
correlates lymphovascular invasion in IBC patients
Carcinoma tissues obtained during MRM showed a significant (p= 0.001) higher CPB2
mRNA expression level compared to normal breast tissues obtained from mammoplasty of
healthy volunteers (Figure 1A). CPB2 mRNA expression level was significantly (p= 0.003)
higher in IBC compared to non-IBC tissue (Figure 1B). Interestingly, carcinoma tissues of
TN breast cancer patients expressed significantly higher level of CPB2 mRNA compared to
HP patients in both non-IBC and IBC groups (p= 0.03 and 0.02, respectively) (Figure 1 C &
D).
Low expression of THBD mRNA in IBC compared to non-IBC carcinoma tissues
Although there was a non-significant difference in THBD mRNA expression between healthy
and breast tissues (Figure 1E), there was a significantly (p= 0.02) lower level in IBC
compared to non-IBC tissue (Figure 1F).

On the other hand, there was no significant

difference in the expression of THBD mRNA expression level in carcinoma tissues of TN
compared to HP patients in both non-IBC and IBC groups (Figure 1 G & H). The THBD
mRNA expression level showed non-significant correlation with CPB2 mRNA expression
level in both non-IBC and IBC patients (Supplementary Table 4). With respect to the
relationship between THBD mRNA expression and clinical pathological data, statistical
analysis detected significant inverse correlations with tumor grade (r= -0.684, p= 0.02) and
lymph node status (r= -0.711, p= 0.005) in both non-IBC and IBC patients.
Expression level of IL-10 is higher in triple negative compared to hormonal positive
IBC patients and positively correlates with CPB2 mRNA expression
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IL10 mRNA is significantly higher (p= 0.01) in breast carcinoma as compared to healthy
breast tissues (Figure 2A). Furthermore, IL10 mRNA expression was significantly (p=0.02)
higher in IBC compared to non-IBC (Figure 2B).

According to molecular subtypes of

patients, we did not detect significant differences in IL10 mRNA expression in TN compared
to HP in the non-IBC sub-group (Figure 2C). On the other hand, in the IBC sub-group IL10
mRNA expression level was significantly higher in TN (p= 0.03) as compared to HP
carcinoma tissues (Figure 2D). In the same manner, IL-10 protein levels were significantly
(p= 0.03) higher in IBC as compared to non-IBC tissue (Figure 2E). IL-10 protein levels did
not differ between TN and HP in non-IBC carcinoma tissues (Figure 2F and 2G), but was
significantly higher in TN as compared to HP IBC carcinoma tissues (Figure 2H and 2I).
IL10 mRNA expression do not correlate with mRNA expression of CPB2 in non-IBC
patients group. However, we detected a significantly positive correlation between mRNA
expression of CPB2 and IL10 in TN (r= 0.783, p= 0.004) and HP (r= 0.625, p= 0.01) in the
IBC patients patient subgroups (Supplementary Table 4).
Expression of CPB2 and IL10 correlate with the presence of lymphovascular invasion in
IBC
CPB2 mRNA expression level showed no correlation with patients’ clinical pathological data
including tumor grade, tumor size and lymph node status in both non-IBC and IBC patients.
However, CPB2 mRNA expression levels significantly (r= 0.766, p= 0.004) correlated with
the presence of lymphovascular invasion in IBC but not non-IBC patients (Figure 3 A & B).
In addition, mRNA expression of IL10 was significantly (r= 0.831, p= 0.002) and positively
correlates with lymphovascular invasion in and IBC patients (Figure 3C).
CPB2 and IL10 mRNA positively correlate with infiltration of CD14+ cells in IBC
carcinoma tissues
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Our previous results showed that CD14+ cells highly infiltrate the carcinoma tissues of IBC
as compared to non-IBC patients. However, we did not detect a significant difference in the
infiltration of CD68+ cells between these two patient groups. Furthermore, we showed that
CD14+ cells isolated from tumor microenvironment of IBC patients highly secrete IL-10 as
compared to non-IBC [36]. Since IL-10 regulates the expression of CPB2 [38], we assessed
the correlation between infiltration of CD14+ cells and the expression of IL10 and CPB2 in
IBC carcinoma tissues. Analysis of IHC staining revealed high infiltration of CD14+ in IBC
carcinoma tissues as compared to non-IBC (Fig. 4 A & B). Expression of CPB2 and IL10
significantly (r= 0.605, p= 0.05 and r= 0.753, p= 0.01, respectively) and positively correlate
with the infiltration of CD14+ cells in IBC carcinoma tissues (Fig. 4 C & D). However, we
did not find any correlation between CPB2 and IL10 mRNA expression and infiltration of
CD68+ cells in either non-IBC or IBC carcinoma tissues (data not shown).
Recombinant IL-10 stimulates the expression of CPB2 mRNA in IBC cell line SUM149
To validate our findings using an in vitro system, we stimulated MDA-MB-231, a TN-nonIBC cell line, and SUM149, a TN-IBC cell line, with varying concentrations of recombinant
IL-10 (100, 200 and 400 ng/ml) for 24h. The mRNA extracted from the treated cells was
subjected to CPB2 and THBD RT-qPCR analysis. Results showed that treatment with IL-10
did not significantly alter CPB2 expression in MDA-MB-231 cells, while CPB2 expression
levels in SUM149 cells were significantly induced (p= 0.04, 0.03 & 0.01) in response to
different concentrations of recombinant IL-10 (100, 200 and 400 ng/ml, respectively) (Figure
5A). On the other hand, recombinant IL-10 did not significantly alter THBD expression in
either MDA-MB-231or SUM149 cell lines (Figure 5B).
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Discussion:
IBC is the most lethal form of breast cancer and is characterized by phenotypes that differ
from other breast cancer. Several studies including ours have shown that IBC disease displays
unusual biological properties. These include rapid progression, metastasis and production of a
unique repertoire of growth factors, cytokines and chemokines, high infiltration of
macrophages/monocytes (CD14+ cells), and detection of multiple viral DNAs compared to
non-IBC [36, 49, 50]. Recent studies have also shown that VTE is more common in IBC
patients [6, 8]. Moreover, high plasma levels of pro-CPB2, a zymogen encoded by CPB2, are
a risk factor for VTE [11].
In the present study, we found that the incidence of CPB2 genotypes carrying the allele
[Thr/Ile (CT) and Ile/Ile (TT)] was significantly higher in breast cancer patients compared to
control population. However, we did not detect any correlation between the incidence of
genotypes carrying the high-risk allele [Thr/Ile (CT) and Ile/Ile (TT)] and tumor grade, tumor
size, lymph node status, ER status, PR status and Her-2 status in either non-IBC or IBC
patients. In agreement with this finding, a study conducted by Fawzy and colleagues found
that incidence of CPB2 genotypes carrying Thr/Ile (CT) and Ile/Ile (TT) allele was higher in
breast cancer patients as compared to healthy patient group, and positively correlates with
pro-CPB2 antigen levels in peripheral blood of Egyptian breast cancer patients. Moreover,
they found that the (Thr/Thr) genotype corresponds to the highest level of plasma pro-CPB2
antigen and the (Ile/Ile) genotype corresponds to the lowest level of plasma pro-CPB2
antigen [19]. We found the CPB2 mRNA expression was higher in breast carcinoma tissues
as compared to normal breast tissues. In addition, CPB2 mRNA expression was higher in
IBC than non-IBC carcinoma tissues. We did not detect any correlation between the
incidence of CPB2 Thr325Ile different genotypes and CPB2 mRNA in breast carcinoma
tissues of either non-IBC or IBC patients.
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The triple negative breast cancer (TNBC) patients currently have no targeted therapies and
are characterized by poor disease prognosis and low survival rate [51].
We found that CPB2 mRNA expression was higher in the carcinoma tissues of TNBC
patients compared to HP patients. On the other hand, female sex steroid hormones were
found to decrease expression of CPB2 mRNA and pro-CPB2 protein in human hepatoma cell
line, in a mechanism mediated by phosphatidylinositol 3-kinase and Akt signaling pathway
and independent of the estrogen receptor [52].
Our results showed that CPB2 expression in breast carcinoma tissues did not show any
significant correlation with tumor size, tumor grade, lymph node involvement, expression of
hormone receptors (ER/PR) and HER-2. However CPB2 expression positively correlated
with presence of lymphovascular invasion in IBC and not in non-IBC patients. Since
lymphovascular invasion is essential for metastasis, this suggests a role for pro-CPB2 in
metastasis. Previous studies have shown an association between pro-CPB2 and metastasis in
Chinese breast cancer patients [18], and with poor prognosis in Egyptian breast cancer
patients [19].
The activation of pro-CPB2 depends on the concentration of TM [53]. We found that mRNA
expression of THBD was lower in the carcinoma tissues of IBC as compared to non-IBC
patients. However, the level of CPB2 mRNA was higher in the carcinoma tissues of IBC
patients; although this may not result in functional CPB2 enzyme due to decreased expression
of THBD in the tumor microenvironment. At the molecular level, THBD mRNA expression
was not correlated with CPB2 mRNA expression in the carcinoma tissues of either non-IBC
or IBC patients. The THBD mRNA expression level found to be significantly and inversely
correlated with tumor grade and lymph node status in both non-IBC and IBC patients. This is
in agreement with a previous study of bladder cancer, which demonstrated that decreased TM
expression level is a predictor of aggressiveness in advanced bladder cancer [54]. TM
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expression was also shown to be decreased in human prostate cancer cell lines, DU-145,
LNCaP and PC-3 as compared to normal prostate epithelial cells PrEC [55].
Our results also demonstrate that IL10 expression was higher in breast carcinoma tissue in
comparison with healthy tissues. This is in agreement with a previous study showing higher
expression levels of IL-10 in breast cancer tissues [34]. Herein, the expression of IL-10 was
higher in IBC as compared to non-IBC carcinoma tissues. Moreover, the IL-10 expression
level was higher in TN-IBC versus HP-IBC tissues. This, in part, supports previous study
showing that IL-10 is over expressed in ER-negative breast tumors as compared to ERpositive carcinoma tissues [56].
It is well established that the tumor microenvironment plays an essential role in breast cancer
progression. Higher infiltration of TAMs in breast carcinoma tissues of IBC is associated
with the secretion of cytokines and growth factors such as IL-10, IL-8, tumor necrosis factoralpha (TNF-α) and CC-chemokine ligand 2 (CCL2) that enhance motility, invasion and the
aggressive properties of IBC [36, 57]. However, the source of CPB2 mRNA in the breast
cancer remains unclear. CPB2 mRNA and pro-CPB2 protein found to be expressed by
macrophages [42]. In the present study, IL10 expression was positively correlated with
infiltration of macrophages in carcinoma and lymphovascular invasion in IBC patients. This
is in agreement with previous study on lung cancer showed that higher mRNA expression of
IL10 by TAMs was associated with advanced stage, tumor size, lymph node metastasis and
lymphovascular invasion [58]. Our results showed that infiltration of CD14+ cells positively
correlates with mRNA expression of IL10 and CPB2 in IBC but not in non-IBC carcinoma
tissues.
CPB2 gene expression is regulated by various cytokines. For instance in acute coronary
syndrome (ACS) there is a positive correlation between IL-1β, IL-6, TNF-α and serum proCPB2 concentration [59]. TNF-α, IL-6 in combination with IL-1β and lipopolysaccharide
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(LPS) decrease transcription of mRNA/pro-CPB2 protein levels by approximately two-fold,
while IL-10 increased pro-CPB2 protein levels by two-fold in a mechanism modulated by
binding of tristetraprolin (TTP) to the CPB2 3'-UTR, [38]. Similarly, we detected a positive
correlation between IL10 and CPB2 expression in the carcinoma tissues of non-IBC and IBC
patients as compared to normal breast tissues of healthy control. These results were validated
in vitro. We found that IL-10 significantly upregulated expression of the CPB2 in the IBC
cell line SUM-149 but not in non-IBC cell line MDA-MB-231, while no significant effect
appeared on THBD expression in either cell lines. Our results suggest that macrophage
infiltration and expression of IL10 in IBC carcinoma tissues may induce the expression of
CPB2.
In conclusion, our study showed that CPB2 and IL10 expression are highly expressed in
carcinoma tissues, and that this increase correlates with lymphovascular invasion in IBC
patients. Furthermore, we demonstrated that the TN patients are characterized by higher
expression of CPB2 as compared to HP patients in each of non-IBC and IBC groups. THBD
expression is down regulated in IBC as compared to non-IBC carcinoma tissues. A potential
mechanism linking patient tumor characteristics with increased CPB2 expression may be
through the high infiltration of CD14+ cells and IL10 in carcinoma tissues of IBC patients.
Thus CPB2 may be regulated by IL-10 in vivo, as demonstrated by the in vitro data. Further
studies are needed to fully understand the role of CPB2 expression, and pro-CPB2 activation
by the thrombin-TM complex, in the etiology of IBC.
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Figures legends:
Figure 1: CPB2 and THBD mRNA expression in non-IBC and IBC patients’ breast
carcinoma tissues. Bars represent CPB2 mRNA expression measured by RT-PCR, (A)
CPB2 is down-regulated in normal compared to carcinoma tissues, (B) Carcinoma tissues of
IBC, overexpress CPB2 mRNA compared to non-IBC (C and D) Carcinoma tissues of TN
patients overexpress CPB2 in non-IBC (C) and IBC (D). Bars represent THBD mRNA
expression in (E) normal breast and carcinoma breast tissues; (F) non-IBC compared to IBC
carcinoma tissues, with significant down-regulation in IBC; (G&H) carcinoma tissues of TN
and HP subgroups of non-IBC (G) and IBC (H). *indicates a signiﬁcant p value, as
determined by Student’s t test.
Figure 2: mRNA and protein expression of IL-10 in non-IBC and IBC patients’
carcinoma tissues. Bars represent (A) RT-PCR results showing down-regulation of IL10
mRNA expression in normal breast tissues as compared to carcinoma breast tissues. (B) IL10
mRNA highly expressed by IBC as compared to non-IBC carcinoma tissues. (C) Nonsignificant difference between the level of expression of IL10 mRNA in TN and HP
subgroups of non-IBC patients. (D) Significant increase in the expression of IL10 by TN
subgroup compared to HP subgroup in IBC patients. (E) Relative density value of IL-10
protein assessed by western blot and normalized against -tubulin, statistical analysis
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revealed that IL-10 protein was significantly over-expressed in IBC compared to non-IBC
carcinoma tissues. (F) Representative IL-10 immunoblots of non-IBC carcinoma tissues (G)
Statistical analysis of immunoblots revealed a non-significant difference in the IL-10
expression in TN and HP subgroups. (H) Representative IL-10 immunoblots in the carcinoma
tissues of IBC patients. (I) Statistical analysis revealed high level of expression of IL-10 in
TN compared to HP carcinoma tissues *indicates a signiﬁcant p value, as determined by
Student’s t test.
Figure 3: CPB2 and IL10 mRNA expression positively correlate with lymphovascular
invasion in IBC tissues. (A) Representative microscopic fields of H&E stained parafﬁn
embedded tissue sections in IBC tissues showing dermal lymphovascular invasion
(magnification: middle panel 10X, while left and right panel 40X). Bars represent the
expression of CPB2 (B) and IL10 (C) in the presence of lymphovascular invasion. *indicates
a signiﬁcant p value, as determined by Chi square test.
Figure 4: CPB2 and IL10 mRNA expression positively correlates with the infiltration
CD14+ cells in IBC carcinoma tissues. (A) Representative fields of microscopic images
showing immunostaining (brown color) of higher expression of CD14 in IBC (n = 15) as
compared to non-IBC (n = 15) carcinoma tissues. (B) Bars represent the infiltration of CD14+
cells in non-IBC and IBC carcinoma tissues. (C&D) Scatter plots showed that CPB2 and
IL10 mRNA expression positively correlates with the infiltration CD14+ cells in IBC
carcinoma tissues. *indicates a signiﬁcant p value, as determined by Student’s t test.
Figure 5: Different concentrations of recombinant IL-10 stimulate the mRNA
expression of CPB2 in SUM149 IBC cell line. RT-PCR analysis detected (A) Significant
increase in the expression of CPB2 mRNA by SUM-149 after stimulation with different
concentrations of recombinant human IL-10 for 24 h. (B) Non-significant change in the
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expression of THBD mRNA by MDA-MB-231 and SUM-149. *indicates a signiﬁcant p
value, as determined by Student’s t test.
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Tables:
Table 1: Clinical and pathological characterization of non-IBC versus IBC patients
Characteristic

Non-IBC
(N = 91)

IBC
(N = 44)

P value

27-78
51.98 ±10.969
1

29-72
49.34 ±11.994
0

0.223

4.6 ±3.5
58 (63.8%)
33 (36.2%)

5.73 ±2.71
16(36.4%)
28(63.6%)

0.003*

10 (11%)
73 (81.3%)
7 (7.7%)

0 (0%)
41 (93.2%)
3 (6.8%)

0.069

4 (4.4%)
74 (80.2%)
14 (15.4%)

0 (0%)
35 (79.5%)
9 (20.5%)

64 (70.3%)
27 (29.7%)

14 (31.8%)
30 (68.2%)

0.002*

75 (82.4%)
16 (17.6%)

14 (31.8%)
30 (68.2%)

0.001*

20 (45.5%)
15 (34.1%)
9 (20.5%)

35 (38.5%)
38 (41.8%)
18 (19.8%)

0.668

19 (43.2%)
15 (34.1%)
10 (22.7%)

42 (46.2%)
31 (34.1%)
18 (19.8%)

0.913

21 (47.7%)
13 (29.5%)
10 (22.7%)

44 (48.4%)
29 (31.9%)
18 (19.8%)

0.915

Age [year]
Range
Mean ±SD
NA

a

Tumor Size [cm]
Mean ±SD
≤4
>4
Pathology
Ductal Carcinoma In Situ
Invasive Ductal Carcinoma
Invasive Lobular Carcinoma
Tumor grade
G1
G2
G3
Axillary Lymph Node Metastasis
≤4
>4
Lymphovascular invasion
Negative
Positive
ER
Negative
Positive
NA
PR
Negative
Positive
NA
Her-2
Negative
Positive
NA
Data are reported as means ±SD
a
Student’s t-test.
b
Chi square test.
* Significant p value (p< 0.05)
NA = not available

a

a

b

0.304

b

b

b

b

b
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Table 2: Genotype and allele frequencies of CPB2 (Thr325Ile) polymorphism among studied
groups using SNPstat software.
Healthy
(n=50)
No (%)

Breast cancer
(n=135)
No (%)

Odds
ratio
(95% CI)

Thr/Thr (CC)

25 (50)

33 (24.4)

1.00

Thr/Ile (CT)

17 (34)

59 (43.7)

0.38 (0.180.80)

0.003*

39 (42.9)

20
(45.5)

Ile/Ile (TT)

8 (16)

43 (31.9)

0.25 (0.100.61)

0.003*

29 (31.9)

14
(31.8)

Thr/Ile (CT) +
Ile/Ile (TT)

25 (50)

102 (75.6)

0.32 (0.160.64)

0.001*

68 (74.7)

34 (77.3)

67 (67)
33 (33)

125 (46)
145 (54)

0.01*

48 (55)
40 (45)

97 (53)
85 (47)

CPB2
Genotypes

Pvalue

Non-IBC
(n=50)
No (%)
23 (25.3)

IBC
(n=135)
No (%)
10
(22.7)

Odds
ratio
(95% CI)

Pvalue

1.00

0.94
(0.412.17)
1.11
(0.422.95)
1.15
(0.492.69)

0.94

0.94

0.75

CPB2 alleles
C
T

0.86
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